These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. Bates AS; Ayers J; Kostakopoulos N; Lumsden T; Schoots IG; Willemse PM; Yuan Y; van den Bergh RCN; Grummet JP; van der Poel HG; Rouvière O; Moris L; Cumberbatch MG; Lardas M; Liew M; Van den Broeck T; Gandaglia G; Fossati N; Briers E; De Santis M; Fanti S; Gillessen S; Oprea-Lager DE; Ploussard G; Henry AM; Tilki D; van der Kwast TH; Wiegel T; N'Dow J; Mason MD; Cornford P; Mottet N; Lam TBL Eur Urol Oncol; 2021 Jun; 4(3):405-423. PubMed ID: 33423943 [TBL] [Abstract][Full Text] [Related]
7. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study. Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883 [TBL] [Abstract][Full Text] [Related]
8. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Valerio M; Cerantola Y; Eggener SE; Lepor H; Polascik TJ; Villers A; Emberton M Eur Urol; 2017 Jan; 71(1):17-34. PubMed ID: 27595377 [TBL] [Abstract][Full Text] [Related]
9. Recurrence rate of localized prostate cancer after radical prostatectomy according to D'amico risk classification in a tertiary referral hospital: association study. Valdez-Vargas AD; Sánchez-López HM; Badillo-Santoyo MA; Maldonado-Valadez RE; Manzo-Pérez BO; Pérez-Abarca VM; Manzo-Pérez G; Vanzzini-Guerrero MA; Álvarez-Canales JA Cir Cir; 2021; 89(4):520-527. PubMed ID: 34352860 [TBL] [Abstract][Full Text] [Related]
10. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587 [TBL] [Abstract][Full Text] [Related]
11. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652 [TBL] [Abstract][Full Text] [Related]
12. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310 [TBL] [Abstract][Full Text] [Related]
13. Contemporary treatments in prostate cancer focal therapy. Ahdoot M; Lebastchi AH; Turkbey B; Wood B; Pinto PA Curr Opin Oncol; 2019 May; 31(3):200-206. PubMed ID: 30865133 [TBL] [Abstract][Full Text] [Related]
14. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure. Azzouzi AR; Lebdai S; Benzaghou F; Stief C World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708 [TBL] [Abstract][Full Text] [Related]
15. The role of focal therapy in the management of localised prostate cancer: a systematic review. Valerio M; Ahmed HU; Emberton M; Lawrentschuk N; Lazzeri M; Montironi R; Nguyen PL; Trachtenberg J; Polascik TJ Eur Urol; 2014 Oct; 66(4):732-51. PubMed ID: 23769825 [TBL] [Abstract][Full Text] [Related]
16. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929 [TBL] [Abstract][Full Text] [Related]
17. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M; Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457 [TBL] [Abstract][Full Text] [Related]
18. Ablation energies for focal treatment of prostate cancer. Lodeizen O; de Bruin M; Eggener S; Crouzet S; Ghai S; Varkarakis I; Katz A; Dominguez-Escrig JL; Pahernik S; de Reijke T; de la Rosette J World J Urol; 2019 Mar; 37(3):409-418. PubMed ID: 29943219 [TBL] [Abstract][Full Text] [Related]
19. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. Eggener SE; Yousuf A; Watson S; Wang S; Oto A J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263 [TBL] [Abstract][Full Text] [Related]
20. Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years. Candela L; Kasraeian A; Barret E Curr Opin Urol; 2022 Mar; 32(2):192-198. PubMed ID: 35013079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]